Articles

Extra-uterine low grade endometrioid stromal sarcoma arising from ovarian endometriosis: a case report and review of the literature

Endometrial stromal sarcoma (ESS) is a rare neoplasm accounting for only 0.2% of female genital tract tumors. The primary extra-uterine location of ESS is an extremely uncommon occurrence.

Authors: Boubacar Efared, Ibrahim S. Sidibé, Fatimazahra Erregad, Nawal Hammas, Laila Chbani and Hinde El Fatemi

Preferences of women with epithelial ovarian cancer for aspects of genetic testing

Although genetic testing is recommended for women with epithelial ovarian cancer (EOC), little is known about patient preferences for various testing options. We measured relative preferences for attributes of...

Authors: Brittany A. Davidson, Jessie Ehrisman, Shelby D. Reed, Jui-Chen Yang, Adam Buchanan and Laura J. Havrilesky

Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy

Widespread concerns have been raised regarding the safety of power morcellation of uterine specimens because of the potential to disseminate occult malignancy. We sought to assess the safety and feasibility of...

Authors: Sarah Dotson, Alejandro Landa, Jessie Ehrisman and Angeles Alvarez Secord

A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer

Ovarian cancer remains a major health problem for women as it is often diagnosed at a late stage with metastatic disease. There are limited therapeutic agents and survival rates remain poor. The perinucleolar ...

Authors: Margaux J. Kanis, Wenan Qiang, Mario Pineda, Kruti P. Maniar and J. Julie Kim

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease ...

Authors: Graziela Zibetti Dal Molin, Carina Meira Abrahão, Robert L. Coleman and Fernando Cotait Maluf

Meeting report, “First Indian national conference on cervical cancer management - expert recommendations and identification of barriers to implementation”

In India, cervical cancer accounts for almost 14% of all female cancer cases. Although poverty continues to cast a wide net over the Indian subcontinent, the preceding three decades have borne witness to impro...

Authors: K. S. Tewari, A. Agarwal, A. Pathak, A. Ramesh, B. Parikh, M. Singhal, G. Saini, P. V. Sushma, N. Huilgol, S. Gundeti, S. Gupta, S. Nangia, S. Rawat, S. Alurkar, V. Goswami, B. Swarup…

The utility of patient reported data in a gynecologic oncology clinic

Measuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient’s cancer treatment especially in non-cl...

Authors: D. Barnes, R. Rivera, S. Gibson, C. Craig, J. Cragun, B. Monk and D. Chase

Socio-demographic characteristics influencing cervical cancer screening intention of HIV-positive women in the central region of Ghana

The burden of HIV and cervical cancer is concentrated in sub-Saharan Africa. Women with HIV are more likely to have persistent HPV infection leading to cervical abnormalities and cancer. Cervical cancer screen...

Authors: Nancy Innocentia Ebu

Improving attendance to genetic counselling services for gynaecological oncology patients

Gynaecological cancers may be the sentinel malignancy in women who carry a mutation in BRCA1 or 2, a mis-match repair gene causing Lynch Syndrome or other genes. Despite published guidelines for referral to a ...

Authors: Hanoon P. Pokharel, Neville F. Hacker and Lesley Andrews

Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management

Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. In contrast to antiangiogenic agents, such as bevacizumab, which ...

Authors: Rachel Grisham, Bonnie Ky, Krishnansu S. Tewari, David J. Chaplin and Joan Walker

Comprehensive knowledge and uptake of cervical cancer screening is low among women living with HIV/AIDS in Northwest Ethiopia

In Ethiopia, cervical cancer is ranked as the second most common type of cancer in women and it is about 8 times more common in HIV infected women. However, data on knowledge of HIV infected women regarding ce...

Authors: Daniel Asfaw Erku, Adeladlew Kassie Netere, Amanual Getnet Mersha, Sileshi Ayele Abebe, Abebe Basazn Mekuria and Sewunet Admasu Belachew

New therapies for advanced, recurrent, and metastatic endometrial cancers

Endometrial cancer is the most common gynecologic malignancy in the United States, accounting for 6% of cancers in women. In 2017, an estimated 61,380 women were diagnosed with endometrial cancer, and approxim...

Authors: Vicky Makker, Angela K. Green, Robert M. Wenham, David Mutch, Brittany Davidson and David Scott Miller

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers

Poly (ADP-ribose) polymerases (PARPs) are an important family of nucleoproteins highly implicated in DNA damage repair. Among the PARP families, the most studied are PARP1, PARP2 and PARP 3. PARP1 is found to ...

Authors: Mekonnen Sisay and Dumessa Edessa

A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer

While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/ca...

Authors: Tran N. Le, Rachel E. Harvey, Christine K. Kim, Jubilee Brown, Robert L. Coleman and Judith A. Smith

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers

Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogeni...

Authors: Jill K. Alldredge and Ramez N. Eskander

Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya

Although cervical cancer is preventable, it is still the second leading cause of cancer deaths among women in the world. Further, it is estimated that around 5–10% of hospital admissions are due to drug relate...

Authors: Amsalu Degu, Peter Njogu, Irene Weru and Peter Karimi

Preparation in the business and practice of medicine: perspectives from recent gynecologic oncology graduates and program directors

Preparation in the business of medicine is reported to be poor across a number of specialties. No data exist about such preparation in gynecologic oncology training programs. Our objectives were to evaluate cu...

Authors: Matthew Schlumbrecht, John Siemon, Guillermo Morales, Marilyn Huang and Brian Slomovitz

Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Therapy for advanced epithelial ovarian cancer (OC) includes first line platinum/taxane-containing chemotherapy and re-treatment with platinum-containing regimens for disease recurrence in patients likely to r...

Authors: Thomas J. Herzog and Bradley J. Monk

Transversus abdominis plane block with liposomal bupivacaine compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer: a cost-effectiveness analysis

To determine the cost-effectiveness of transversus abdominis plane block with liposomal bupivacaine (TAP) compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early e...

Authors: Brandon-Luke L. Seagle, Emily S. Miller, Anna E. Strohl, Anna Hoekstra and Shohreh Shahabi

Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes

Due to the significant morbidity and mortality associated with placenta percreta, alternative management options are needed. Beginning in 2005, our institution implemented a multidisciplinary strategy to patie...

Authors: Paula S. Lee, Samantha Kempner, Michael Miller, Jennifer Dominguez, Chad Grotegut, Jessie Ehrisman, Rebecca Previs, Laura J. Havrilesky, Gloria Broadwater, Sarah C. Ellestad and Angeles Alvarez Secord

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001

Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacteria...

Authors: Brett Miles, Howard P. Safran and Bradley J. Monk

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy

Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as ...

Authors: Brett A. Miles, Bradley J. Monk and Howard P. Safran

Erratum to: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana

Authors: Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore and Philippe Mayaud

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis ...

Authors: Bradley J. Monk, Warner K. Huh, Julie Ann Rosenberg and Ira Jacobs

Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as...

Authors: Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter…

Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana

Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has be...

Authors: Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore and Philippe Mayaud

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature

Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the BRCA1/2 genes. However, through germline and tumor sequencing an understanding of the larger...

Authors: Melissa K. Frey and Bhavana Pothuri

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report

Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 bl...

Authors: Sarah E. Paraghamian, Teresa C. Longoria and Ramez N. Eskander

Clinical features and treatment of vulvar Merkel cell carcinoma: a systematic review

Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently ...

Authors: Austin Huy Nguyen, Ahmed I. Tahseen, Adam M. Vaudreuil, Gabriel C. Caponetti and Christopher J. Huerter

Disparities in the surgical staging of high-grade endometrial cancer in the United States

The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. O...

Authors: Jonathan R. Foote, Stephanie Gaillard, Gloria Broadwater, Julie A. Sosa, Brittany Davidson, Mohamed A. Adam, Angeles Alvarez Secord, Monica B. Jones, Junzo Chino and Laura J. Havrilesky

New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care

Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distin...

Authors: A. Talhouk and J. N. McAlpine

Genetic testing in a gynaecological oncology care in developing countries—knowledge, attitudes and perception of Nepalese clinicians

Genetic testing for an inherited susceptibility to cancer is an emerging technology in medical practice. Little information is currently available about physicians’ attitudes towards these tests in developing ...

Authors: Hanoon P Pokharel, Neville F Hacker and Lesley Andrews

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis

Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemor...

Authors: Brittany A. Davidson, Jonathan Foote, Stacey L. Brower, Chunqiao Tian, Laura J. Havrilesky and Angeles Alvarez Secord

The role of immune checkpoint inhibition in the treatment of ovarian cancer

The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical eff...

Authors: Stéphanie L. Gaillard, Angeles A. Secord and Bradley Monk

Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies

The Fifth Annual Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies was held at and sponsored by the Division of Gynecologic Oncology at the the University of Calif...

Authors: Krishnansu S. Tewari

Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success

Cervical cancer is the fourth most common cancer among women worldwide, many of who are still within their reproductive lifespan. Advances in screening and treatment have increased the 5-year survival for earl...

Authors: Karla Willows, Genevieve Lennox and Allan Covens

Fertility preservation in women with cervical, endometrial or ovarian cancers

Although cancer in general affects an aged population, a significant number of women develop cancer at childbearing age. Long-term survival rates after gynecological cancer, especially in young patients are in...

Authors: Michael Feichtinger and Kenny A. Rodriguez-Wallberg

Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review

The management of patients with recurrent gynecological malignancy is complex, and often contentious. While historically, patients with metastases in the lungs, liver or brain have been treated with palliative...

Authors: Neville F. Hacker and Archana Rao

Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer

Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometria...

Authors: Michelle Glasgow, Rachel Isaksson Vogel, Jennifer Burgart, Peter Argenta, Kathryn Dusenbery and Melissa A. Geller

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a n...

Authors: Munetaka Takekuma, Kwong K. Wong and Robert L. Coleman

Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study

After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in treati...

Authors: Lindsey E. Minion, Dana M. Chase, John H. Farley, Lyndsay J. Willmott and Bradley J. Monk

New treatment option for ovarian cancer: PARP inhibitors

Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein enzymes involved in DNA damage response and works by recognizing the single-strand DNA break (...

Authors: Robert S. Meehan and Alice P. Chen

Erratum to: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm

Authors: Teresa C. Longoria and Ramez N. Eskander

Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy

Many women who develop endometrial cancer (EC) or endometrial hyperplasia with atypia are obese and therefore at high risk of surgical complications. Recently clinical trials have been initiated offering non-s...

Authors: Andreas Obermair, Donal J. Brennan, Eva Baxter, Jane E. Armes, Val Gebski and Monika Janda

Lumbosacral plexopathy: A rare long term complication of concomitant chemo-radiation for cervical cancer

Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact on quality of life. Its occurrence is rare but increasing with improved long-term cancer surviva...

Authors: Imane Bourhafour, Meriem Benoulaid, Hanane El Kacemi, Sanae El Majjaoui, Tayeb Kebdani and Noureddine Benjaafar

Immunotherapy in endometrial cancer - an evolving therapeutic paradigm

Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease...

Authors: Teresa C. Longoria and Ramez N. Eskander

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience

Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease are poor. Thus, new therapeutic strategies are urgently required.

Authors: Siqing Fu, Naiyi Shi, Jennifer Wheler, Aung Naing, Filip Janku, Sarina Piha-Paul, Jing Gong, David Hong, Apostolia Tsimberidou, Ralph Zinner, Vivek Subbiah, Ming-Mo Hou, Pedro Ramirez, Lois Ramondetta, Karen Lu and Funda Meric-Bernstam

Clinico-epidemiological profile of molar pregnancies in a tertiary care centre of Eastern Nepal: a retrospective review of medical records

The incidence of molar pregnancy has demonstrated marked geographic and ethnic differences. The reported data in Nepal is inconsistent with minimal published literature. Thus, we designed a study to determine ...

Authors: Nimisha Agrawal, Reshu Agrawal Sagtani, Shyam Sundar Budhathoki and Hanoon P. Pokharel

Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future

Despite the introduction of screening and, latterly, vaccination programs in the developed world, globally cervical cancer remains a significant health problem. For those diagnosed with advanced or recurrent d...

Authors: Victor Rodriguez-Freixinos and Helen J. Mackay

Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution)

Cervical cancer (CC) is one of the most widespread gynecological malignancies in women worldwide. Treatment strategies and screening modalities have largely evolved these past years resulting in an improvement...

Authors: J. Khalil, S. Bellefqih, N. Sahli, M. Afif, H. Elkacemi, S. Elmajjaoui, T. Kebdani and N. Benjaafar